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and associates with favorable 
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Marcus Tius1, Maarit Tiirikainen1, Charles Rosser5, Haining Yang1 & Herbert Yu1* 
Long non‑coding RNAs (lncRNAs) have important biological functions, but their involvement in 
ovarian cancer remains elusive. We analyzed high‑throughput data to identify lncRNAs associated 
with ovarian cancer outcomes. Our search led to the discovery of lncRNA TOPORS Antisense RNA 1 
(TOPORS‑AS1). Patients with high TOPORS‑AS1 expression had favorable overall survival compared 
to low expression. This association was replicated in our study and confirmed by meta‑analysis. 
In vitro experiments demonstrated that overexpressing TOPORS‑AS1 in ovarian cancer cells 
suppressed cell proliferation and inhibited aggressive cell behaviors, including migration, invasion, 
and colony formation. Analysis of tumor cell transcriptomes indicated TOPORS‑AS1′s influence 
on the Wnt/β‑catenin signaling. Additional experiments revealed that TOPORS‑AS1 increased the 
phosphorylation of β‑catenin and suppressed the expression of CTNNB1, disrupting the Wnt/β‑
catenin pathway. Our experiments further discovered that vitamin D receptor (VDR) upregulated 
TOPORS‑AS1 expression and that inhibition of β‑catenin by TOPORS‑AS1 required a RNA binding 
protein, hnRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2B1). Taken together, these findings 
suggest that TOPORS‑AS1 may behave like a tumor suppressor in ovarian cancer through interrupting 
the Wnt/β‑catenin signaling and that VDR upregulates the expression of TOPORS‑AS1. Assessing 
TOPORS‑AS1 expression in ovarian cancer may help predict disease prognosis and develop treatment 
strategy
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IP  Immunoprecipitation
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Ovarian cancer is a lethal gynecological disease, and the 5-year survival rate is dismal, only 47%1. As most 
patients are diagnosed with an advanced disease, few effective therapies are available for ovarian cancer treatment. 
Currently, there are no reliable tests available to detect ovarian cancer early. Biomarkers for accurate prediction 
of disease outcome and treatment response are also limited. Studies of ovarian cancer mechanisms have largely 
focused on proteins and their coding genes. Since protein-coding genes account for only 2% of the human 
 genome2, our understanding of ovarian cancer development and progression from the genome perspective 
remains inadequate. Lately, long non-coding RNAs (lncRNAs), which contain 200 nucleotides or more with no 
or limited protein-coding potential, have been recognized to have crucial roles to play in regulation of biological 
functions and cellular activities. Emerging evidence also suggests that lncRNAs play a role in cancer, including 
ovarian  cancer3–9. Understanding the involvement of lncRNAs in ovarian cancer may provide new insights and 
offer novel opportunities for diagnosis, prognosis, and treatment. In search for lncRNAs which might be impli-
cated in ovarian cancer, we analyzed ovarian cancer survival in association with many lncRNAs whose expression 
data are available online in public databases. Our search led us to find the expression of TOPORS Antisense RNA 
1 (TOPORS-AS1) significantly associated with overall and progression-free survival of ovarian cancer.
Vitamin D receptor (VDR) is a nuclear receptor which binds to its ligand, 1, 25-dihydroxyvitamin  D3, and 
acts as a transcription factor in regulating important cellular activities and functions, such as immunity, cell 
proliferation, differentiation and  apoptosis10. VDR is known to have strong anti-tumor properties, including 
suppression of proliferation and inflammation, promotion of differentiation and apoptosis, as well as inhibition 
of angiogenesis and tumor cell invasion and  metastasis11. VDR is expressed in the ovaries and is involved in the 
regulation of estrogen biosynthesis and aromatase  activity12–14. Increasing VDR expression in ovarian cancer 
cells inhibits cell proliferation and tumor  growth15. Evidence also suggests that VDR may interact with lncRNAs 
to exert its  functions16. VDR was found to increase the expression of MEG3 (maternally expressed gene 3), a 
tumor suppressor in  ovarian17 and colorectal  cancers18. In this report, we discussed our discovery of lncRNA 
TOPORS-AS1 whose expression was regulated by VDR, associated with ovarian cancer survival, and able to 
inhibit the Wnt/β-catenin signaling.
Results
Association of TOPORS‑AS1 expression with disease stage and patient survival. Data from our 
study (Table 1) showed that TOPORS-AS1 expression was higher in early (Stage I or II) than late stages (Stage III 
or IV) of ovarian cancer (p = 0.0046). TOPORS-AS1 expression was not different between serous and non-serous 
tumors, nor changed by tumor grade or patient age at surgery. High expression of TOPORS-AS1 was found to 
be associated with favorable overall survival, and the association remained significant after adjusting for patient 
age, disease stage, tumor grade and histology (Table 2). In comparison to those with low TOPORS-AS1, patients 
with high expression had over 40% reduction in risk of death (HR = 0.58, 95% CI 0.34–0.99, p = 0.046). Risks for 
disease progression, however, were not significantly different between patients with high and low TOPORS-AS1 
expression regardless of their clinicopathological features.
Using the Kaplan–Meier Plotter to analyze an online dataset of 1566 patients, we found that TOPORS-AS1 
expression was associated with both overall and progression-free survivals. Patients with high TOPORS-AS1 
had lower risk of death and disease progression compared to those with low expression (Fig. 1A,B), although 
our study showed a significant association only with overall survival, not progression-free survival (Fig. 1C,D).
Combining our study with 5 GEO (GSE14764, GSE30161, GSE18520, GSE26193, and GSE26712) and one 
TCGA datasets which contained information on survival outcomes and TOPORS-AS1 expression in ovarian 
cancer, we performed a meta-analysis on the association between ovarian cancer survival and TOPORS-AS1 
expression in a total of 1,157 patients. The results showed that patients with high expression of TOPORS-AS1 
had a significantly reduced risk of death, Hazard Ratio (HR) = 0.73, 95% CI 0.55–0.91 (Fig. 1E). Among the 7 
datasets, 4 had information on progression-free survival, including GSE30161, GSE26193, TCGA and our study, 
and the meta-analysis showed no significant association between TOPORS-AS1 expression and progression-free 
survival, HR = 0.84, 95% CI 0.58–1.21 (Fig. 1F).
TOPORS‑AS1 expression in ovarian cancer cells. TOPORS-AS1 expression was measured in 6 ovar-
ian cancer cell lines (IGROV1, SKOV3, OVCAR3, OVCAR4, OVCAR5, OVCAR8) with RT-qPCR, and none of 
the tested cell lines showed high expression of this lncRNA (Fig. 2A). To assess its effect on ovarian cancer cells, 
we constructed a TOPORS-AS1 plasmid and transfected two cell lines (IGROV1, SKOV3) to make stable over-
expression of the lncRNA. Compared to the mock cells, TOPORS-AS1 expression was about 60-fold higher in 
the transfected IGROV1 and 150-fold higher in transfected SKOV3 (Fig. 2B,C). We evaluated cell proliferation, 
migration, invasion, and colony formation in these transfected cells. The experiments showed that TOPORS-AS1 
overexpression led to reduced cell proliferation, migration, invasion, and colony formation (Fig. 2D–K). These 
results were consistent in both cell lines (Supplemental Figure S1A,B).
To confirm the above effects from TOPORS-AS1, we treated the TOPORS-AS1 overexpressing cells (SKOV3, 
IGROV1) with siRNAs targeting the lncRNA. After the treatment, TOPORS-AS1 expression was significantly 
decreased in the cells (Fig. 2L,M). Compared to the control cells (treated with scrambled siRNAs), cells with 
TOPORS-AS1 knockdown had increased proliferation, migration, and invasion (Fig. 2N,S), and the results were 
consistent in both cell lines (Supplemental Figure S1C).
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Interaction between TOPORS‑AS1 and the Wnt/β‑catenin pathway. To investigate the effect of 
TOPORS-AS1 in ovarian cancer, we compared the transcriptomes of SKOV3 and IGROV1 with and without 
TOPORS-AS1 overexpression using the Human Transcriptome Array 2.0 (Affymetrix). Figure 3A,B are heat-
maps of the differentially expressed genes (DEGs) related to TOPORS-AS1 overexpression in IGROV1 and 
SKOV3, respectively. There were 51 up-regulated and 6 down-regulated genes (fold change ≥ 1.5 and p < 0.05) 
which were shared by both cell lines. This list of DEGs was uploaded to IPA for interrogation of the biological 
networks involving TOPORS-AS1 overexpression. As shown in Fig. 3C, the involvement of Wnt/β-catenin was 
suggested in both cell lines overexpressing TOPORS-AS1.
To determine if the Wnt/β-catenin signaling was involved, we analyzed several major components of the path-
way in the transfected cells. Figure 3D shows the results of our western blot analysis in which we found increased 
phosphorylation of β-catenin and decreased levels of β-catenin, LEF1, TCF1/TCF7, and c-Myc in TOPORS-AS1 
overexpressing cells. GSK3β, both total and phosphorylated form (Y216), showed no changes. As phosphoryla-
tion of β-catenin leads to its degradation which results in suppression of the Wnt/β-catenin signaling, our results 
support the IPA prediction that TOPORS-AS1 may interrupt the Wnt/β-catenin pathway in ovarian cancer.
To further assess the lncRNA’s effect on β-catenin, we analyzed the β-catenin gene (CTNNB1) expression in 
cells with and without TOPORS-AS1 overexpression. Our qPCR results showed that levels of β-catenin mRNA 
were significantly reduced in IGROV1 and SKOV3 overexpressing TOPORS-AS1, compared with the mock cells 
(Supplemental Figure S2), suggesting that TOPORS-AS1 overexpression may suppress both β-catenin transcrip-
tion and phosphorylation.
RIP assay was performed to determine if TOPORS-AS1 interacts with β-catenin in IGROV1 and SKOV3. 
The analysis showed no direct interaction between these molecules (data not shown), suggesting that the effect 
of TOPORS-AS1 on β-catenin may involve or act through other molecules.
Interaction between TOPORS‑AS1 and hnRNPA2B1. In search for molecules which may interact 
with TOPORS-AS1, we used an online program  NPInter19 that makes in silico prediction between RNAs and 
proteins. The software predicted several candidate molecules which may contain putative regions interactive 
with TOPORS-AS1. Among them, hnRNPA2B1 (heterogeneous nuclear ribonucleoproteins A2/B1) was shown 
to have a binding site in the exon region of TOPORS-AS1. This hypothetic interaction was supported by our RIP 
assay in which hnRNPA2B1 was shown to interact with TOPORS-AS1 both in IGROV1 and SKOV3 (Fig. 3E–H). 
Using co-immunoprecipitation, we also found that hnRNPA2B1 could interact with β-catenin, and the interac-
tion was observed in both cell lines (Fig. 3I,J). As mentioned earlier, TOPORS-AS1 overexpression could reduce 
the level of β-catenin. When we suppressed the expression of hnRNPA2B1 with siRNA, β-catenin was increased 
Table 1.  Associations of TOPORS-AS1 with clinicopathological factors of ovarian cancer. Bold indicates 
p<0.05.
Variables Total no. (N = 242)
TOPORS-AS1 expression
P valueLow, no. (%) Mid, no. (%) High, no. (%)
Age at surgery
 ≤ 59.08 114 (47.70) 36 (31.58) 40 (35.09) 38 (33.33)
0.92
 > 59.08 125 (52.30) 42 (33.60) 41 (32.80) 42 (33.60)
Disease stage
I–II 65 (27.08) 16 (24.62) 17 (26.15) 32 (49.23)
0.0046
III–IV 175 (72.92) 64 (36.57) 64 (36.57) 47 (26.86)
Tumor grade
1–2 64 (26.56) 20 (31.25) 22 (34.38) 22 (34.38)
0.92
 ≥ 3 177 (73.44) 60 (33.90) 60 (33.90) 57 (32.20)
Histologic type
Non-serous 145 (59.92) 46 (31.72) 52 (35.86) 47 (32.41)
0.72
Serous 97 (40.08) 34 (35.05) 30 (30.93) 33 (34.02)
Table 2.  Associations of TOPORS-AS1 with ovarian cancer survival. PFS progression-free survival, OS overall 








Adjusted  OSa P 
valueHR 95% CI HR 95% CI HR 95% CI HR 95% CI
Low 1 1 1 1
Mid 0.73 0.47–1.14 0.16 0.85 0.53–1.34 0.48 0.76 0.49–1.17 0.21 0.89 0.55–1.40 0.58
High 0.75 0.49–1.16 0.10 0.49 0.29–0.82 0.0069 0.995 0.64–1.55 0.98 0.58 0.34–0.99 0.046
Continuous 0.87 0.69–1.08 0.21 0.71 0.55–0.91 0.0068 0.99 0.79–1.25 0.94 0.77 0.60–0.999 0.049
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Figure 1.  Kaplan–Meier survival curves in ovarian cancer patients with high and low TOPORS-AS1 
expression. (A) Kaplan–Meier overall survival curves by high (upper tertile) and low (lower tertile) expression 
of TOPORS-AS1 from online Kaplan–Meier Plotter. (B) Kaplan–Meier progression-free survival curves by 
high (upper tertile) and low (lower tertile) expression of TOPORS-AS1from online Kaplan–Meier Plotter. (C) 
Kaplan–Meier overall survival curves by high (upper tertile) and low (lower tertile) expression of TOPORS-AS1 
from our study. (D) Kaplan–Meier progression-free survival curves by high (upper tertile) and low (lower 
tertile) expression of TOPORS-AS1 from our study. (E) Forest plots for associations between TOPORS-AS1 
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in the cells overexpressing TOPORS-AS1 (Fig. 3K), suggesting that hnRNPA2B1 may be required in the inhibi-
tion of β-catenin by TOPORS-AS1.
Interaction between TOPORS‑AS1 and VDR. PROMO predicted that vitamin D receptor (VDR) was a 
transcription factor of TOPORS-AS1, and a VDR binding site in the lncRNA’s promoter, from − 1470 to − 1478, 
was suggested (Fig. 4A). To validate the VDR binding site, we made a VDR vector, pCMV_VDR, which was 
transfected to 293 T cells. The transfection increased VDR expression in the cells (Fig. 4B), and the increase in 
VDR expression led to elevated luciferase activities in the cells co-transfected with a wild-type TOPORS-AS1 
promoter, but not in those with a mutant promoter (Fig. 4C). The binding between VDR and the TOPORS-AS1 
promoter was confirmed by chromatin immunoprecipitation (Fig. 4D).
After confirming the interaction between VDR and TOPORS-AS1 in 293 T cell, we evaluated the VDR 
effects on tumor cells by transfecting IGROV1 and SKOV3 with the VDR plasmid. Our experiments showed 
that the VDR-transfected tumor cells had reduced β-catenin (Fig. 4E) and increased TOPORS-AS1 expression 
(Fig. 4F,G). VDR transfection also led to decreased cell proliferation (Fig. 4H,I), migration (Fig. 4J,K), and inva-
sion (Fig. 4L,M). The results were consistent in both cell lines (Supplemental Figure S3). To examine if the VDR 
effect on β-catenin was mediated through TOPORS-AS1, we transfected IGROV1 and SKOV3 first with VDR 
(Fig. 5A,B) and then TOPORS-AS1 siRNAs (Fig. 5C,D). After siRNA knockdown, we observed no β-catenin 
suppression (Fig. 5E,F), and cell proliferation was increased (Fig. 5G,H), suggesting that TOPORS-AS1may 
mediate the VDR effect on tumor cells.
We also evaluated if TOPORS-AS1 overexpression in ovarian tumor cells could increase the expression of 
VDR which subsequently suppressed tumor proliferation. Our experiments showed that VDR expression did 
not change over time in IGROV1 and SKOV3 after TOPORS-AS1 transfection (Fig. 5J,L), but cell proliferation 
was suppressed in the transfected cells (Fig. 5I,K), indicating that TOPORS-AS1 does not affect the expression 
of VDR and the lncRNA suppresses cell proliferation, not VDR.
Discussion
In this study, we found that ovarian cancer patients with early-stage disease tended to have high TOPORS-AS1 in 
the tumor and that high expression was associated with favorable overall survival compared to low expression. 
This survival association was not affected by disease stage and tumor histology and replicated in several inde-
pendent datasets. A meta-analysis of 1157 patients confirmed the association between TOPORS-AS1 and overall 
survival. Results of our in vitro experiments supported the finding in patients, demonstrating that TOPORS-AS1 
expression in ovarian cancer cells inhibited tumor cell proliferation, migration, invasion, and colony formation. 
Further investigation of biological function and molecular regulation revealed that TOPORS-AS1 interacted with 
hnRNPA2B1 and increased the phosphorylation of β-catenin which led to its degradation, resulting in suppres-
sion of the Wnt/β-catenin signaling pathway. Our experiments also discovered that VDR was a transcription 
factor for TOPORS-AS1 and that the suppression of ovarian cancer cells by VDR could be mediated through 
TOPORS-AS1. The relationships among TOPORS-AS1, VDR, β-catenin, and hnRNPA2B1 are depicted in Fig. 6.
TOPORS-AS1 is encoded by a gene in chromosome 9p21, and the gene has a 554 bp transcript (NR_033992.2). 
The function and regulation of this transcript was not known before. We found in the study that TOPORS-AS1 
expression was different by disease stage, but not by tumor histology or grade, suggesting that the lncRNA’s 
expression may be affected by the size or time of tumor growth, but not by the type or differentiation of tumor 
cells. Our finding of no difference in expression between serous and non-serous tumors also indicates that 
the biomarker may have broader clinical implications in ovarian cancer, not only to those high-grade serous 
tumors. Our study showed that TOPORS-AS1′s association with survival was only observed consistently in 
overall survival, but not in progression-free survival. It is unclear what the reasons for this discrepancy are, but 
we acknowledge the fact that progression-free survival of ovarian cancer is difficult to assess consistently across 
studies compared to overall survival given its high mortality.
The finding of high TOPORS-AS1 in association with favorable ovarian cancer survival is in agreement with 
the observations of two previous studies by Su et al.20 and Sorenson et al.21 in breast cancer. In addition, our 
finding of VDR in regulation of TOPORS-AS1 expression is also in line with the understanding of VDR’s role in 
 cancer22. VDR belongs to the superfamily of steroid hormone  receptors23, and the protein is expressed in many 
organs including the ovaries where it regulates important cellular activities and biological  functions15,24. VDR 
is known to be a strong tumor suppressor and is able to inhibit ovarian cancer cell  growth15. We found in the 
study that VDR was able to bind to the TOPORS-AS1 promoter, upregulating its expression. Our experiments 
also indicated that TOPORS-AS1 could mediate the inhibitory effects of VDR on cell proliferation, migration, 
and invasion.
Our study further suggests that TOPORS-AS1 may play a role in connection to the reciprocal suppression 
between VDR and the Wnt/β-catenin pathway in ovarian  cancer25. It is known that VDR deficiency leads to 
increased Wnt/β-catenin signaling in colon  cancer26. When the pathway is activated, β-catenin is translocated 
from cytoplasm to nucleus where it binds to LEF/TCF to increase the expression of Myc and Cyclin D1, pro-
moting cell migration and tumor progression. When deactivated, β-catenin is released from the APC/Axin/
GSK3β complex in cytoplasm, undergoing phosphorylation and  degradation27. In various human malignancies 
including ovarian cancer, the Wnt/β-catenin signaling is highly  activated28,29. Defects in APC or β-catenin were 
found in colorectal cancer, which stabilized β-catenin, resulting in constitutive activation of the Wnt/β-catenin 
 pathway30–32. Evidence suggests that the Wnt/β-catenin pathway is also important in ovarian  cancer28,33–35.
A number of lncRNAs have been identified to influence or regulate the Wnt/β-catenin  pathway36–41. In our 
experiments, we found increased TOPORS-AS1 expression in ovarian cancer cells after VDR transfection, and 
these increases in expression of TOPORS-AS1 and VDR resulted in decreased β-catenin expression and increased 
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phosphorylation of β-catenin, leading to suppression of the Wnt/β-catenin pathway. To evaluate which one, VDR 
or TOPORS-AS1, was responsible for the change in β-catenin, we added si-TOPORS-AS1 in cell culture and 
found that the decline in β-catenin was abolished after TOPORS-AS1 knockdown, suggesting that the lncRNA 
may mediate the effect of VDR on β-catenin. Our experiments further indicated no direct interaction between 
TOPORS-AS1 and β-catenin, and the effect of TOPORS-AS1 on β-catenin involved an RNA-binding protein. We 
found that hnRNPA2B1 was able to interact with both TOPORS-AS1 and β-catenin. This protein is a member of 
the heterogeneous nuclear ribonucleoprotein family which functions as a splicing factor to process and stabilize 
pre-mRNAs. MYU (c-Myc-upregulated lncRNA) associates with the RNA binding protein hnRNP-K to stabilize 
CDK6 expression, and the lncRNA is a direct target of the Wnt/c-Myc  pathway5. It was found that hnRNPA2 
could interact with the 3′-UTR of CTNNB1, affecting the expression of CTNNB1 and β-catenin42. In our study, 
β-catenin levels were decreased by TOPORS-AS1 through its interaction with hnRNPA2B1. Without the RNA-
binding protein, the effect of TOPORS-AS1 on β-catenin was not observed, suggesting that both TOPORS-AS1 
and hnRNPA2B1 are required in their action on β-catenin.
In summary, our study showed that high expression of lncRNA TOPORS-AS1 was associated with favorable 
prognosis of ovarian cancer. In vitro experiments demonstrated that TOPORS-AS1 behaved like a tumor suppres-
sor in ovarian cancer as the lncRNA could suppress cell proliferation, migration, invasion, and colony formation. 
Furthermore, TOPORS-AS1 increased β-catenin degradation and inhibited the expression of CTNNB1, suppress-
ing the Wnt/β-catenin signaling. Our experiments also found that VDR was able to bind to the TOPORS-AS1 
promoter, upregulating its expression, and that TOPORS-AS1 could mediate the inhibitory effects of VDR on 
cell proliferation, migration, and invasion. The effect of TOPORS-AS1 on β-catenin in ovarian cancer relied on 
the presence of hnRNPA2B1. Taken together, these findings suggest that TOPORS-AS1 is a tumor suppressor 
in ovarian cancer and that assessing the lncRNA level in tumor tissue may help to predict the disease prognosis 
and design treatment strategy.
Materials and methods
Study patients. To study epithelial ovarian cancer, we recruited 266 patients who were operated in two 
hospitals affiliated with the University of Turin in Italy. The recruitment was approved by the AOU Citta della 
Salute’s ethic review committee and the Mauriziano hospital’s eithic review committee, and informed consents 
were obtained from the patients. All the study protocols were performed in accordance with relevant guide-
lines and regulations. Disease stage was determined based on the International Federation of Gynecology and 
Obstetrics (FIGO) Classification, and tumor histology and grade were characterized according to the WHO 
 Guidelines43,44. Detailed description of the study patients is provided in Supplemental Materials and Methods S1.
Tumor samples and RNA extraction. Fresh tumor samples were collected from the patients during sur-
gery, and the samples were evaluated independently by two pathologists to confirm tumor cell contents (> 80% 
tumor cells). The tissue specimens were pulverized using a tissue homogenizer. Approximately 30 mg of pulver-
ized tissue powder was used for total RNA extraction, using the AllPrep DNA/RNA Mini kit (Qiagen). After 
extraction, total RNAs were treated with RNase-free DNase to remove DNA contamination. The purity and 
quantity of the RNA samples were evaluated with specific light absorbances and RNA Integrity Number (RIN). 
The same methods were also used for RNA extraction and quantification from cell lines.
RT‑qPCR. A high capacity cDNA reverse transcription kit was used to convert total RNA to cDNA (Applied 
Biosystems). The cDNA samples were analyzed for expression of TOPORS-AS1, CTNNB1 and GAPDH, using 
the SYBR Green-based quantitative PCR. PCR primer sequences are shown in Supplemental Table S1. Details of 
the analysis are provided in Supplemental Materials and Methods S1.
Cell culture. The NCI-60 DTP Human Tumor Cell Screening Panel was purchased from NIH for research by 
the High-throughput Drug Screening Core at University of Hawaii Cancer Center (UHCC). From the panel we 
selected six ovarian cancer cell lines for testing, including OVCAR3, OVCAR4, OVCAR5, OVCAR8, IGROV1, 
and SKOV3. The 293 T cell line was purchased from the American Type Culture Collection (ATCC). All the cells 
Figure 2.  Inhibition of ovarian cancer cell proliferation, invasion, migration, and colony formation by 
TOPORS-AS1. (A) RT-qPCR results showing TOPORS-AS1 expression in 6 ovarian cancer cell lines. (B,C) 
RT-qPCR results showing increased TOPORS-AS1 expression in IGROV1 and SKOV3 after TOPORS-AS1 
transfection. (D,E) Cell proliferation assay showing slower proliferation of IGROV1 and SKOV3 after 
TOPORS-AS1 transfection. (F,G) Cell transwell migration assay showing reduced cell migration in IGROV1 
and SKOV3 after TOPORS-AS1 transfection. (H,I) Cell transwell invasion assay showing reduced cell invasion 
in IGROV1 and SKOV3 after TOPORS-AS1 transfection. (J,K) Colony formation assay showing fewer colonies 
formed in IGROV1 and SKOV3 after TOPORS-AS1 transfection. (L,M) RT-qPCR results showing reduced 
TOPORS-AS1 expression after si-TOPORS-AS1 knockdown in IGROV1 and SKOV3 transfected with the 
TOPORS-AS1 plasmid. (N,O) Cell proliferation assay showing increased cell proliferation after si-TOPORS-AS1 
knockdown in IGROV1 and SKOV3 transfected with the TOPORS-AS1 plasmid. (P,Q) Cell transwell migration 
assay showing increased cell migration after si-TOPORS-AS1 knockdown in IGROV1 and SKOV3 transfected 
with the TOPORS-AS1 plasmid. (R,S) Cell transwell invasion assay showing increased cell invasion after 
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Figure 3.  Transcriptomic analysis of ovarian cancer cells associated with TOPORS-AS1 expression and 
discovery of β-catenin involvement. (A,B) Heatmap of differentially expressed genes due to TOPORS-AS1 
overexpression in IGROV1 and SKOV3. (C) IPA results of common pathways associated with TOPORS-AS1 
overexpression in both IGROV1 and SKOV3. (D) Western blot results showing reduced β-catenin, LEF1, 
TCF1/TCF7 and c-Myc, increased phosphorylation of β-catenin, and no changes in GSK3β (either total or 
phosphorylated) in both IGROV1 and SKOV3 due to TOPORS-AS1 overexpression. (E,G) Western blot results 
showing the pulldown of hnRNPA2B1 in mock and TOPORS-AS1 transfected IGROV1 and SKOV3. (F,H) RIP 
results showing marked enrichment of TOPORS-AS1 in cell extracts processed with anti-hnRNPA2B1 antibody 
pulldown, but not in IgG pulldown, from IGROV1 and SKOV3. (I,J) Co-immunoprecipitation (IP) results 
suggesting β-catenin binding to hnRNPA2B1 in IGROV1 and SKOV3. (K) Western blot results showing that 
β-catenin suppression by TOPORS-AS1 could be reversed by knockdown hnRNPA2B1 through si-hnRNPA2B1 
in IGROV1 and SKOV3. ***P < 0.0001; **P < 0.001.
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Figure 4.  Upregulation of TOPORS-AS1 expression by VDR and its effect on tumor cell proliferation, 
migration, and invasion. (A) PROMO prediction of a VDR binding site in the TOPORS-AS1 promoter. (B) 
Western blot results showing increased VDR expression in 293 T after transfecting the cells with a pCMV_VDR 
plasmid. (C) Luciferase reporter assay results showing increased luciferase activity in 293 T cells co-transfected 
with the VDR plasmid (pCMV_VDR) and luciferase reporter gene linked to TOPORS-AS1-wt (wild type) and 
no increase in TOPORS-AS1-mut (mutated). (D) Chromatin immunoprecipitation (ChIP) results suggesting 
VDR binding to the TOPORS-AS1 promoter. (E) Western blot results showing increased VDR and decreased 
β-catenin in IGROV1 and SKOV3 after VDR transfection. (F,G) RT-qPCR results showing increased 
TOPORS-AS1 expression in IGROV1 and SKOV3 after VDR transfection. (H,I) Cell proliferation assay showing 
slower IGROV1 and SKOV3 proliferation after VDR transfection. (J,K) Cell transwell migration assay showing 
fewer migrated IGROV1 and SKOV3 after VDR transfection. (L,M) Cell transwell invasion assay showing fewer 
invaded IGROV1and SKOV3 after VDR transfection. ***P < 0.0001; **P < 0.001.
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were cultured in RPMI 1640 medium containing 10% FBS and 100 units/ml of penicillin/streptomycin (Pen/
Strep) at 37 °C under a humidified atmosphere containing 5%  CO2.
Plasmid construction and amplification. Based on the transcript NR_033992.2 (554 bp), a TOPORS-
AS1 template was synthesized by GENEWIZ and inserted into a lentiviral vector, pCDH-EF1-MCS-pA-PGK-
copGFP-T2A-Puro (System Biosciences), with two restriction sites, Nhe1 and BamH1. The plasmid contains two 
promoters, EF1 which controls the expression of TOPORS-AS1 and PGK which drives a report gene, GFP, serv-
ing as a transfection control. The expression of TOPORS-AS1 from the plasmid was verified by direct sequencing 
and gel electrophoresis after restriction enzyme digestion. For plasmid amplification, please see details in Sup-
plemental Materials and Methods S1.
Plasmid transfection and stable cell selection. Ovarian cancer cell lines, IGROV1 and SKOV3, were 
selected for transfection either with pCDH_TOPORS-AS1 or pCDH_vector (mock), using the Lipofectamine 
3000 reagent (Thermo Fisher Scientific). Details of plasmid transfection and cell selection are provided in Sup-
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Figure 5.  TOPORS-AS1 mediates the effect of VDR on ovarian cancer cells. (A,B) Western blot results 
showing reduced β-catenin in IGROV1 and SKOV3 after VDR transfection. (C,D) RT-qPCR results showing 
TOPORS-AS1 knockdown by si-TOPORS-AS1 in VDR-transfected IGROV1 and SKOV3. (E,F) Western blot 
results showing increased β-catenin after TOPORS-AS1 knockdown by si-TOPORS-AS1 in VDR-transfected 
IGROV1 and SKOV3. (G,H) Increased cell proliferation in VDR-transfected IGROV1 and SKOV3 after 
TOPORS-AS1 knockdown by si-TOPORS-AS1. (I,K) Decreased cell proliferation in IGROV1 and SKOV3 
after transfection with TOPORS-AS1. (J,L) Western blot results showing no change in VDR levels over time in 
IGROV1 and SKOV3 after transfection with TOPORS-AS1. ***P < 0.0001; **P < 0.001.
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Cell proliferation assay. Ovarian cancer cells in 100 μl complete medium were added into the wells of 
96-well plates at a density of 3 ×  103 cells per well. After 0, 24, 48, and 72 h of incubation, 10 μl cell proliferation 
reagent WST-1 was added into each well following the manufacturer’s instructions (Roche). The cells were incu-
bated with WST-1 for 2 more hours at 37 °C in a humidified atmosphere containing 5%  CO2 before the plate was 
read with a microplate reader (BioTek Synergy 2, Winooski, VT) at 450 nm absorbance. Cell proliferation at each 
time point was normalized to the mean viable cells at 0 h. Each proliferation assay was performed in triplicate.
Cell migration and invasion assays. Cell migration and invasion were analyzed in 24-well plates using 
the Costar Transwell permeable membrane support with 8.0-μm pore size (Corning). In the invasion assay, ovar-
ian cancer cells, 1 ×  104 cells per well, in 200 μl serum-free medium were placed in the upper chambers coated 
with growth-factor-reduced Matrigel at 1 mg/ml (BD Pharmingen). The lower chambers were filled with 600 μl 
complete culture media containing 10% FBS. Cell migration assays were performed similarly without Matrigel 
coating. Invaded or migrated cells were stained with HEME 3 Solution (Fisher Diagnostics) after 36 h of culture, 
and the stained cells were photographed using the Olympus CKX41 microscopy with an Infinity 2 camera. Cell 
numbers were counted using the ImageJ software. All the experiments were repeated 3 times, and each experi-
ment was done in triplicate.
Colony formation assay. The assay has been described  elsewhere8. In brief, ovarian cancer cells (5 ×  103) 
were seeded on 0.3% agarose overlaid onto solidified 0.6% agarose in PRMI 1640 with 10% FBS. Complete 
medium (200 µl) was added into the well every three days. Cell colonies were counted after three weeks. The 
experiments were repeated 3 times.
siRNA assay. Ovarian cancer cells with stable expression of TOPORS-AS1 were transfected with the Target 
Long Noncoding RNA siRNA-SMART pool (#R-189076-00-0005) to knockdown TOPORS-AS1 expression, and 
Lincode Non-targeting Pool (#D-001320-10-05) was used as a negative control, both of which were purchased 
from Dharmacon. The transfection was performed following the manufacturer’s protocol for Lipofectamine 
RNAiMAX (Themo Fisher Scientific). The transfected cells were prepared for analysis after 36 h of incubation.
Analysis of cell transcriptome. The transcriptomes of IGROV1 and SKOV3 with and without TOPORS-
AS1 overexpression were analyzed with the Affymetrix Human Transcriptome Array 2.0 (Affymetrix). DNA 
labeling, probe hybridization, and signal scanning were completed by the Genomics Shared Resource at UHCC. 
Figure 6.  Schematic illustration of TOPORS-AS1 regulated by VDR, interacting with hnRNPA2B1, and 
inhibiting the Wnt/β-catenin signaling.
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The initial array data were normalized using the robust multi-array average RMA algorithm in the Affymetrix 
Expression Console (Affymetrix). Gene-based differential expression were analyzed using the Transcriptome 
Analysis Console (TAC) v3.0 (Affymetrix). Differentially expressed genes, defined as fold change ≥ 1.5 and p 
value < 0.05, were interrogated with the Ingenuity Pathway Analysis (IPA) software to predict the possible sign-
aling pathways and regulatory mechanisms associated with TOPORS-AS1 overexpression. PROMO (http:// 
alggen. lsi. upc. es/ cgi- bin/ promo_ v3/ promo/ promo init. cgi? dirDB= TF_8.3) was employed with 5% dissimilarity 
to predict the potential transcription factors and their possible binding sites in the TOPORS-AS1  promoter45,46. 
NPInter (https:// www. bioin fo. org/ NPInt er/) was used to show possible interactions between TOPORS-AS1 and 
other  molecules19.
RNA immunoprecipitation (RIP). EZ-Magna RIP RNA-Binding Protein Immunoprecipitation kit (#17-
701, Millipore) was used for RIP assay. Antibody against β-catenin (ab6302) was purchased from Abcam. Rabbit 
IgG antibody (#12-370 from EMD Millipore) was used as control. RIP assay was performed according to the 
manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP). ChIP assay was carried out using a commercial kit from EMD 
Millipore. Plasmids (pCMV-vector or pCMV-VDR) were transfected to 293 T cells using the Lipofectamine 
3000 reagent (Themo Fisher Scientific). Details of the ChIP assay are described in Supplemental Materials and 
Methods S1.
Dual luciferase reporter assay. A plasmid (pCMV-VDR) containing a full-length human VDR and a 
vector (pGL4.27[luc2P/minP/Hygro]) were purchased from Origene Technologies and Promega, respectively. 
GENEWIZ synthesized wild and mutant TOPORS-AS1 promoters and inserted the sequences into the pGL4.27 
vector to make pGL4.27-TOPORS-AS1-wt and pGL4.27-TOPORS-AS1-mut plasmids. pCMV-VDR or pCMV-
vector were transiently transfected to the 293 T cells using Lipofectamine 3000 reagent (Themo Fisher Scientific). 
After transfection, cells were incubated for 36 h and further transfected with plasmid pGL4.27-TOPORS-AS1-wt 
or pGL4.27-TOPORS-AS1-mut, together with the renilla reporter vector. After incubation, renilla and firefly 
luciferase activities were measured using the Dual-Luciferase kit (Promega). The results were normalized to the 
renilla reporter to adjust for transfection efficiency. Each assay was performed in triplicate, and the assays were 
repeated three times.
Immunoblotting. Cell proteins were extracted using the RIPA Lysis and Extraction Buffer (Themo Fisher 
Scientific). Concentrations of the extracted proteins were measured with the BCA assay, and 40–60 µg of the 
proteins were boiled in the Laemmli Sample Buffer (Bio-Rad) at 95℃ for 5 min, followed by 10% SDS–PAGE. 
The gel results were transferred onto the polyvinylidene difluoride (PVDF) membranes (Millipore) which were 
then blocked with 5% non-fat milk for 30 min and incubated with a primary antibody, followed by a second-
ary antibody to generate the signals detectable by an enhanced chemiluminescence system (Pierce). Primary 
antibodies used for blotting included anti-VDR (#12550 from Cell Signaling Technology), anti-hnRNPA2B1 
(ab6102 from Abcam), anti-β-catenin (ab6302 from Abcam), anti-p-β-catenin (ser33/37/thr41) (#9561 from 
Cell Signaling Technology), anti-β-catenin (#8480 from Cell Signaling Technology), anti-LEF1 (#2230 from Cell 
Signaling Technology), anti-TCF1/TCF7(#2203 from Cell Signaling Technology), anti-cMYC (#18583 from Cell 
Signaling Technology), anti-p-GSK3β(Y216) (ab75745 from Abcam), anti-GSK3β (#12456 from Cell Signaling 
Technology, and anti-β-actin (A2228 from Sigma-Aldrich) antibodies.
Immunoprecipitation (IP). Cells were cultured to 70% confluence and lysed in the Pierce IP Buffer 
(Themo Fisher Scientific). To purify proteins, cell lysates (600–800 μg) were incubated with 30 μl of the Pierce 
Protein A/G Magnetic Beads (Themo Fisher Scientific) for 30 min at 4 °C on rotation. After bead removal and 
overnight incubation at 4 °C with anti-β-catenin antibody (2–4 μg/mg protein), the protein solution was mixed 
with 30 μl of the Protein A/G Magnetic Beads, and the mixture was incubated for another 2 h. Then, the beads 
were washed three times with washing buffer and once with PBS, and were further mixed with the Laemmli 
Sample Buffer, followed by boiling at 95 °C for 5 min. After that, the solution was processed with 10% SDS–
PAGE, and the resulting gels were transferred to the PVDF membranes, followed by incubation with another 
antibody (anti-hnRNPA2B1) and ECL measurement (Bio-Rad).
Meta‑analysis. Using the keywords “ovarian cancer” and “ovarian carcinoma”, we searched the Gene 
Expression Omnibus (GEO) in NCBI (https:// www. ncbi. nlm. nih. gov/ gds). Datasets with more than 50 tumor 
samples as well as information on TOPORS-AS1 expression and survival outcomes were selected for analysis. 
Five datasets meeting the criteria were identified in the database, including GSE14764, GSE30161, GSE18520, 
GSE26193, and GSE26712. The Cancer Genome Atlas (TCGA) data on TOPORS-AS1 expression in ovarian 
cancer were also downloaded from TANRIC (https:// www. tanric. org), and clinical information related to the 
dataset was retrieved from cBioPortal (http:// www. cbiop ortal. org)47,48. Hazard ratios (HR) and 95% confidence 
intervals (95% CI) were calculated for each of the datasets, and these results were entered into the Review Man-
ager 5.3 to obtain summary HR and 95% CI, using the random-effect  model49.
Statistical analysis. Expression index (EI) was calculated as levels of TOPORS-AS1 expression after adjust-
ing for the GAPDH expression, and the calculation was based on the formula 1000 ×  2(−∆Ct), where ∆Ct is the dif-
ference in cycle thresholds (Ct) between  CtTOPORS-AS1 and  CtGAPDH. For data analysis, the EI values were classified 
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into low, middle, and high groups, based on the tertile distribution of TOPORS-AS1 expression. The expression 
data were analyzed for associations with clinical and pathological variables, using the chi-square test. Log-rank 
test was used to compare the Kaplan–Meier survival curves between high and low expression of TOPORS-
AS1, and the median was used as cutoff. Hazard ratios (HR) and 95% confidence interval (CI) were calculated 
using the Cox proportional hazards regression model, univariate and multivariate. In the multivariate model, 
age at surgery, disease stage, tumor grade and histology type were included as covariates to control for con-
founding factors. Two survival outcomes, progression-free and overall survivals, were used in survival analysis. 
Progression-free survival was the time interval from the date of surgery to the date of disease progression or last 
follow-up. Overall survival was the duration between surgery and last follow-up or death. SAS (version 9.4) and 
R (version 3.0.2) were used for statistical analyses. All p-values were two-sided.
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